---
title: "Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints"
description: "Aclaris Therapeutics Inc :ACLARIS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL INHIBITOR OF ITK AND JAK3; TRIAL A"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250662154.md"
published_at: "2025-07-29T21:19:54.000Z"
---

# Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints

> Aclaris Therapeutics Inc :ACLARIS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL INHIBITOR OF ITK AND JAK3; TRIAL ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTSACLARIS THERAPEUTICS INC - PRIMARY ENDPOINT CONFIRMS FAVORABLE TOLERABILITY PROFILE OF ATI-2138ACLARIS THERAPEUTICS INC - ATI-2138 WELL TOLERATED WITH NO SEVERE ADVERSE EVENTS

Aclaris Therapeutics Inc :

-   ACLARIS THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL INHIBITOR OF ITK AND JAK3; TRIAL ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS
-   ACLARIS THERAPEUTICS INC - PRIMARY ENDPOINT CONFIRMS FAVORABLE TOLERABILITY PROFILE OF ATI-2138
-   ACLARIS THERAPEUTICS INC - ATI-2138 WELL TOLERATED WITH NO SEVERE ADVERSE EVENTS

### Related Stocks

- [ACRS.US - Aclaris Therap](https://longbridge.com/en/quote/ACRS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 | Aclaris Therapeutics (NASDAQ: ACRS) presented its development priorities and milestones for its biologics and oral small | [Link](https://longbridge.com/en/news/275827675.md) |
| Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy | Aclaris Therapeutics has expanded its inflammation and immunology pipeline, focusing on innovative therapies for Th1-, T | [Link](https://longbridge.com/en/news/272270423.md) |
| Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 | Aclaris Therapeutics, Inc. (ACRS) reported positive interim results from a Phase 1a trial of ATI-052, indicating it was  | [Link](https://longbridge.com/en/news/271653199.md) |
| Ascelia Pharma AB reports full year 2025 operating result of SEK -74.4M, earnings per share of SEK -0.67, and liquid assets of SEK 49.9M | Ascelia Pharma AB reported its full year 2025 financial results, showing an operating result of SEK -74.4 million and ea | [Link](https://longbridge.com/en/news/274926047.md) |
| Aclaris Therapeutics to Present at Major Healthcare Conferences | Aclaris Therapeutics Inc. will participate in two healthcare conferences in February 2026. CEO Dr. Neal Walker and senio | [Link](https://longbridge.com/en/news/274807454.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.